Radiotherapy for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to assess how prostate tumors respond to a new type of radiotherapy, called Specially Adjusted Radiation Treatment for Prostate, which uses only two sessions instead of many. The researchers aim to determine if concentrating more radiation on specific tumor areas can be safe and effective. Participants will divide into two groups, each receiving different treatment and imaging schedules to fine-tune the radiation doses. Men diagnosed with certain types of prostate cancer who have not yet received pelvic radiotherapy might be suitable for this study.
As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants the opportunity to contribute to significant advancements in prostate cancer therapy.
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are on androgen deprivation therapy or 5-alpha reductase therapy, you cannot participate in the trial.
What prior data suggests that this radiotherapy protocol is safe for prostate cancer treatment?
Research has shown that hypofractionated radiation therapy, which involves fewer sessions with higher doses of radiation, is generally well-tolerated by prostate cancer patients. Studies have found that it can improve long-term outcomes without causing more severe side effects. Specifically, patients who underwent shorter radiation treatments reported fewer issues with bowel, urinary, and sexual health.
However, some risks exist. Men receiving radiation therapy for prostate cancer may face a higher chance of developing bladder cancer compared to those who do not receive radiation. Despite this, the overall safety of this treatment appears acceptable, and it does not significantly increase severe side effects.
For those considering joining a trial for this type of radiation treatment, it's important to weigh the benefits of shorter treatment time against the potential risks. Consulting a healthcare provider can help determine how it might fit an individual's specific situation.12345Why are researchers excited about this trial?
Researchers are excited about these specially adjusted radiation treatments for prostate cancer because they offer a more personalized approach than traditional methods. Unlike standard care, which often involves a uniform radiation schedule, this trial tailors the treatment to the patient’s response. Arm 1 tests a five-week course with an MRI midway to customize further treatment, while Arm 2 compresses the therapy into a three-week period with targeted radiation based on MRI findings. This approach aims to maximize effectiveness and minimize unnecessary exposure, potentially improving outcomes and reducing side effects.
What evidence suggests that this specially adjusted radiation treatment could be effective for prostate cancer?
This trial will compare two specially adjusted radiation treatment schedules for prostate cancer. One group of participants will receive five fractions of radiotherapy over five weeks, with or without additional treatment to their pelvic lymph nodes, and an MRI midway through the treatment to assess the response. Another group will receive a single fraction of radiation, followed by a second MRI after three weeks, and then a second fraction based on the MRI results. Studies have shown that specially adjusted radiation treatments, such as SBRT (stereotactic body radiation therapy), can effectively treat prostate cancer in just five sessions, achieving excellent results. Research indicates that patients receiving higher doses of radiation each day experience similar cancer control and side effects as those undergoing traditional, longer treatments. Additionally, using radiation to treat pelvic lymph nodes proves effective with advanced techniques like IMRT (intensity-modulated radiation therapy), which targets the cancer precisely while protecting healthy tissue. These findings suggest that shorter, focused radiation treatments could be a promising option for prostate cancer.14678
Are You a Good Fit for This Trial?
This trial is for people with prostate cancer who are eligible to receive radiation therapy. Participants should be able to undergo MRI scans and follow the treatment schedule. Those with conditions that prevent safe participation or interfere with imaging may not qualify.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation Treatment - Stage 1
Participants receive 5 fractions of radiotherapy to their prostate with or without radiotherapy to their pelvic lymph nodes. An MRI is conducted midway to assess response.
Radiation Treatment - Stage 2
Participants receive a single fraction of radiation to the prostate +/- pelvis with extra radiation to any nodule(s)/tumors identified on MR. A second MR is conducted after 3 weeks, followed by a second fraction of radiation.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of GI toxicity, PSA levels, and quality of life.
What Are the Treatments Tested in This Trial?
Interventions
- Specially Adjusted Radiation Treatment for Prostate
Trial Overview
The study tests a new way of giving radiation for prostate cancer, using just two sessions tailored to each person based on MRI results after the first session. The goal is to see if this personalized approach is safe and effective.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
The second group of 25 patients enrolled in this study will receive a single fraction of radiation to the prostate +/- pelvis with extra radiation to any nodule(s)/tumors in the prostate identified on MR. They will then have a second MR after 3 weeks and based on that MR a second fraction of radiation to the prostate +/- pelvis will be delivered.
The first group of 25 patients enrolled will receive 5 fractions of radiotherapy to their prostate with or without radiotherapy to their pelvic lymph nodes and an MRI midway through the treatment to assess the response of disease.
Find a Clinic Near You
Who Is Running the Clinical Trial?
AHS Cancer Control Alberta
Lead Sponsor
Citations
Fifteen-Year Outcomes after Monitoring, Surgery, or ...
More than three quarters of these men underwent surgery within 2 years after diagnosis and 84% received salvage radiotherapy, treatments that ...
Comparative Effectiveness of Different Radical Radiotherapy ...
In this study, men treated with EBRT combined with HDR-BT had a 36% lower risk of prostate cancer death compared with those treated with CF EBRT to 78 Gy, and ...
Outcomes of prostate cancer treatments - BJU International
Men receiving radiation therapy had a 2.78-times greater risk of developing bladder cancer and a 100-fold increase in the risk of radiation ...
Real-world comparative outcomes and toxicities after ...
This study showed that the treatment outcomes of PBT for prostate cancer potentially surpassed those of IMRT, particularly concerning bRFS and ...
Study confirms safety and efficacy of higher-dose-per-day ...
The analysis found patients who received isodose MHFRT (60 Gy in 20 fractions) had similar cancer control and side effects compared to those ...
Comparison of outcomes and toxicities among radiation ...
Differences in overall survival, distant metastasis, and cancer specific mortality (5-year rates: 82–97%, 1–14%, 0–8%, respectively) have not been detected in ...
7.
urologytimes.com
urologytimes.com/view/hypofractionated-radiation-therapy-improves-10-year-prostate-cancer-outcomesHypofractionated radiation therapy improves 10-year ...
Hypofractionated radiation therapy improves 10-year prostate cancer outcomes ... New data presented at the American Society for Radiation ...
Long-Term Adverse Effects and Complications After ...
Moreover, among participants treated with radiotherapy, there was a nearly 3-fold greater hazard risk of bladder cancer than in the untreated ( ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.